Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-尾/R, CXCR4, CSF-1R, CD47-SIRP伪, Adenosine, STING & Others

Publication ID:

LMP1216002

Publication Date:

December 8, 2016

Pages:

117

Publisher:

La Merie Publishing

Countries:

Global [1]

USD 770.00

Pharma & Healthcare [2]

Healthcare [3]

Description:

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-尾/R, CXCR4, CSF-1R, CD47-SIRP伪, Adenosine, STING & Others

This Competitive Intelligence report about听Tumor Microenvironment Modulation via IDO, TGF-尾/R, CXCR4, CSF-1R, CD47-SIRP伪, Adenosine, STING & Others evaluates as of December 2016 the competitive field of mainly inhibitors and antagonists of substrates, enzymes and receptors involved in the immunosuppressive tumor microenvironment, including

IDO (Indoleamine 2,3-dioxygenase
TDO (Tryptophan 2,3 dioxygenase)
TGF-尾/R (Transforming Growth Factor beta/Receptor)
CXCR4 (Chemokine Receptor Type 4)
CSF-1R (Colony Stimulating Factor-1 Receptor)
CD47 鈥� SIRP伪 (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others (e.g. arginase)

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

More than 45 new听 molecular entities modulating the immunosuppressive tumor microenvironment are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further eight molecules are undergoing IND-enabling studies.

The report includes a compilation of currently active projects in research and development of modulators of the tumor microenvironment. In addition, the report lists company-specific R&D pipelines of Tumor Microenvironment Modulators. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table Of Contents:

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-尾/R, CXCR4, CSF-1R, CD47-SIRP伪, Adenosine, STING & Others

Table of Contents

1) IDO & TDO Inhibitors

Epacadostat Studies
Indoximod Studies
Novel IDO Inhibitors
Novel TDO Inhibitors
Dual IDO & TDO Inhibitors

2) TGF-beta/R Inhibitors

3) CXCR4 Antagonists & CXCL12 Inhibitors

4) CSF-1R Antagonists & CSF-1R tk Inhibitors

5) CD47 鈥� SIRP伪 Pathway Inhibition

6) Adenosine Pathway

Adenosine A2 Receptor (A2AR) Antagonists
CD73 (AMPase) & CD39 (ATP/ADPase) Inhibitors and Adenosine Degradation

7) STING Receptor Stimulators

8) Other Inhibitors of Immunosuppressive Tumor Microenvironment

9) Corporate Tumor Microenvironment Modulator R&D Pipelines

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂